Takeda walks away from Omontys

Share this article:

Takeda and Affymax are parting ways. PMLive reports that Takeda is withdrawing its US marketing application for the anemia drug Omontys and that Affymax is not looking to pick the marketing rights up.

The companies had to recall the drug last year after several patient deaths and allergic reactions. Takeda told PMLive that it looked into the reactions and found they could not be attributed to quality or manufacturing issues.

PMLive says Affymax had three employees as of March, and was running a deficit of around $560 million.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Miss Idaho shows off diabetes pump

NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."

Roche is hungry, not starving for M&A

CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.

AbbVie nabs Shire for $54B

AbbVie, in the latest example of a US drugmaker seeking to lower its tax rate, said today that it's buying Dublin-based Shire for $54 billion.